2018 American Transplant Congress
Higher Rates of Rejection in HIV-Infected Kidney Transplant Recipients on Ritonavir-Boosted Protease Inhibitors–Three-Year Follow Up
The Mount Sinai Hospital, New York.
Background: One-year rejection rates in HIV-infected kidney transplant recipients range from 15-40%, compared to overall rejection rates of 10% in HIV-negative patients. Protocols for immunosuppression…2018 American Transplant Congress
Efficacy and Safety of Immediate- and Prolonged-Release Tacrolimus in De Novo Pediatric Transplantation: Randomized Study
This study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) vs immediate-release tacrolimus (IR-T) in de novo pediatric transplant pts. Phase II, parallel-group, multicenter, open-label study…2018 American Transplant Congress
MeltDose Prolonged-Release Once-Daily Tacrolimus (LCPT) vs. Conventional Tacrolimus Formulations in the Initial Maintenance of De Novo Kideny Transplant Recipients across Europe: STEADY Study
Tacrolimus is an immunosuppressant drug available as a twice-daily formulation (Prograf®, IR-Tac), or as once-daily formulations (Advagraf®, PR-Tac; Envarsus®, LCPT). LCPT has shown clinical non-inferiority…2018 American Transplant Congress
Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients- 3 Years Follow-Up
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…2018 American Transplant Congress
Treatment of BK Viremia: Single-Center Experience
Nephrology, University of Kentucky, Lexington, KY.
INTRODUCTION:BK viremia (BKV) and BK virus nephropathy (BKVN) is recognized as an emerging problem in renal transplant recipients. Only reduction of immunosuppressants had shown efficacy…2018 American Transplant Congress
Exploring Immunosuppressant Medication Adherence in Kidney Transplant Recipients
Imperial College Renal and Transplant Centre, London, United Kingdom.
IntroductionNonadherence to immunosuppressive medication is associated with poor outcomes following kidney transplantation. The aim of this study was to describe the beliefs, understanding and experience…2018 American Transplant Congress
Association of Immunosuppressive Therapy Regimen with Sepsis Outcomes among Kidney Transplant Recipients
OBJECTIVE: Immunosuppressive therapy (IST) could impact sepsis outcomes by altering the host immune response. We examined the associations of IST regimens with sepsis outcomes among…2018 American Transplant Congress
Polyclonal Cellular Immune Function is Dose-Dependently Inhibited by Immunosuppressive Drugs but Has Limited Value in Predicting Infection or Rejection Episodes
1Saarland University, Homburg/Saar, Germany; 2Saarland University, Homburg/Saar, Germany.
Background: Dosage of immunosuppressive drugs in transplant patients must be balanced to prevent graft rejection and infectious complications. Knowledge on general immune function may therefore…2018 American Transplant Congress
Islet Xenotransplantation: A Quest for Clinically Available Immunosuppression Regimens
Department of Surgery, Duke University Medical Center, Durham, NC.
IntroductionThe field of porcine islet xenotransplantation has made significant progress in non-human primate studies in recent years. However, one major barrier preventing clinical translation of…2018 American Transplant Congress
Experience with Immunosuppressive Strategies in Vascularized Composite Allotransplantation of Face
This retrospective review of the largest face transplant cohort aims to describe the evolution of immunosuppressive (IS) regimens used in face transplant recipients.All face transplants…
- « Previous Page
- 1
- …
- 74
- 75
- 76
- 77
- 78
- …
- 138
- Next Page »